IUPAC: (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile · C20H21FN2O · MW 324.40 g/mol · CAS 128196-01-0
Escitalopram (Lexapro / Cipralex). The pure (S)-enantiomer of citalopram and the most target-selective SSRI ever marketed — it does essentially one thing: block the serotonin transporter (SERT) with single-digit-nanomolar potency. Its story is a lesson in stereochemistry: the abandoned (R)-mirror image is not inert ballast but an allosteric brake on the active enantiomer. Marketed as escitalopram oxalate (2002).
Escitalopram is a selective serotonin reuptake inhibitor. It binds the deep, occluded central S1 pocket of the sodium-dependent serotonin transporter (SERT / SLC6A4) — the same orthosteric site that normally captures 5-HT for reuptake — and locks the transporter in an outward-open, transport-incompetent conformation. Reuptake stops; synaptic serotonin rises. Unlike cocaine (which blocks DAT, NET and SERT indiscriminately) or MDMA (a SERT substrate that reverses transport), escitalopram is a pure competitive occluder with the highest SERT selectivity of any SSRI — it barely touches NET, DAT, or the monoamine receptor panel.
The defining structural feature: escitalopram also occupies a second, allosteric S2 site in the extracellular vestibule, ~11 Å above S1. This was resolved directly by X-ray crystallography of human SERT with (S)-citalopram bound at both sites (Coleman, Green & Gouaux, 2016, Nature 532:334; PDB 5I73). Occupancy of S2 slows the drug's dissociation from S1 — a self-potentiating allosteric effect that prolongs functional inhibition beyond what the S1 Ki alone predicts.
Escitalopram inserts into the 5-HT orthosteric pocket between TM1, TM3, TM6 and TM8, coordinating the same subsites (A, B, C) the substrate uses. Na⁺/Cl⁻-coupled alternating access is frozen: Ki ≈ 1.0 nM (ChEMBL).
A second escitalopram molecule binds the scaffold-domain vestibule (S2). This allosteric occupancy sterically caps the release pathway and slows koff from S1 — the biochemical basis of escitalopram's durable inhibition (PDB 5I73).
The (S)-enantiomer carries essentially all SERT inhibitory potency (Ki ~1 nM vs ~36 nM for (R)-citalopram). Removing the (R)-mirror image is why escitalopram outperforms racemic citalopram milligram-for-milligram.
(R)-citalopram is not inert: it binds the allosteric S2 site and antagonizes the (S)-enantiomer's action, reducing its net SERT inhibition. In racemic citalopram, R blunts S — an effect abolished by giving pure escitalopram.
Negligible affinity at NET, DAT, muscarinic, histaminergic (H₁), α-adrenergic, dopaminergic and serotonin receptors. This receptor "silence" is why escitalopram is clean on sedation, weight and anticholinergic burden relative to TCAs.
At higher concentrations escitalopram weakly blocks the cardiac hERG (Kv11.1) potassium channel, delaying repolarization. This is the molecular origin of its dose-dependent QT prolongation and the regulatory dose cap.
Net downstream pharmacology is delayed, not acute: SERT blockade raises 5-HT within minutes, but the therapeutic antidepressant effect requires weeks — the interval during which somatodendritic 5-HT1A autoreceptors desensitize, disinhibiting raphe firing and restoring forebrain serotonergic tone. The cascade below traces the mechanism from transporter to circuit.
Escitalopram has clean, linear pharmacokinetics: good oral bioavailability (~80%), moderate protein binding (~56%), and a long half-life (~27–32 h) supporting once-daily dosing. Clearance is dominated by hepatic N-demethylation via CYP2C19 (with minor CYP3A4 and CYP2D6 contributions) to S-desmethylcitalopram (S-DCT) and then S-didesmethylcitalopram (S-DDCT) — metabolites that are markedly weaker SERT inhibitors than the parent and do not meaningfully drive effect.
Metabolism cascade: serial N-demethylation of the dimethylaminopropyl chain, each step stripping SERT potency.
CYP2C19 poor metabolizers (~2–5% of Europeans, ~15% of East Asians) and patients on CYP2C19 inhibitors (omeprazole, fluvoxamine, cimetidine) reach roughly 50% higher plasma exposure. Because escitalopram's QT liability is exposure-dependent, the label caps the dose at 10 mg/day in CYP2C19 poor metabolizers, the elderly, and hepatic impairment — versus a 20 mg/day ceiling otherwise. This is a pharmacokinetic guardrail against a pharmacodynamic (hERG) risk.
S-DCT and S-DDCT cross the blood–brain barrier poorly and contribute little to central effect; escitalopram's action is essentially all parent drug. Renal excretion of unchanged drug is minor (~8%), so dose reduction is driven by hepatic — not renal — function.
Escitalopram's clinical identity is selectivity. It is first-line for major depressive disorder and generalized anxiety disorder precisely because it lacks the receptor promiscuity of the TCAs and the CYP-inhibition baggage of some older SSRIs. But two features define its risk-benefit: the stereochemistry that makes it work, and the cardiac channel that caps its dose.
SERT blockade in raphe projection fields (prefrontal cortex, hippocampus, amygdala) elevates 5-HT tone. The therapeutic lag (2–6 weeks) reflects the time required for 5-HT1A autoreceptor desensitization and downstream neuroplastic adaptation (BDNF/TrkB signaling), not the near-instant transporter blockade itself. This dissociation between molecular onset and clinical onset is central to SSRI pharmacology.
Racemic citalopram is a 50:50 mix of (S)- and (R)-citalopram. The (S)-form does the work; the (R)-form is a weak SERT ligand (Ki ~36 nM) that binds the allosteric S2 site and negatively modulates (S)-citalopram's inhibition — it partially cancels its own better half. Escitalopram removes (R) entirely, so 10 mg of escitalopram delivers more effective SERT inhibition than 20 mg of citalopram, with faster onset in some trials. This is the rare case where a "me-too" single-enantiomer switch is genuinely pharmacologically superior (Sánchez et al., 2014).
Escitalopram (and its metabolite S-DDCT) weakly blocks the hERG / Kv11.1 potassium channel that mediates cardiac repolarization (IKr). The QTc increase is modest and concentration-dependent — a mean ~4–6 ms at 10 mg, larger at supratherapeutic exposure — but it is real and cumulative with other QT-prolonging drugs. This is why the dose is capped at 20 mg/day generally and 10 mg/day in CYP2C19 poor metabolizers and the elderly, and why baseline ECG/electrolytes matter in at-risk patients. Escitalopram's QT signal is genuinely smaller than racemic citalopram's, but it is not zero.
Sustained serotonergic tone downstream drives the class side-effect profile: sexual dysfunction (delayed orgasm, low libido — often the main adherence-limiter), initial GI upset and activation/anxiety in the first 1–2 weeks, and, on abrupt cessation, a discontinuation syndrome. Escitalopram's ~30 h half-life makes its discontinuation milder than short-half-life paroxetine, but taper is still required.
The through-line: escitalopram is the pharmacological argument that "selective" is a spectrum, and that even a near-single-target drug carries an off-target liability (hERG) that governs its dosing envelope. Its efficacy is unremarkable among SSRIs; its tolerability and selectivity are what keep it first-line.
Escitalopram is a hybrid rigid/flexible ligand. Its dihydroisobenzofuran core bearing the
4-fluorophenyl and cyano substituents is a rigid, pre-organized aromatic platform, while the
3-(dimethylamino)propyl tail is a flexible, freely rotating chain (5 rotatable bonds).
In FlexAID∆S entropy modeling this splits the binding thermodynamics: the rigid head pays almost no
ΔS_conf penalty on docking into S1, while the amine tail must freeze into a single
gauche conformation to salt-bridge Asp98 — a localized entropy cost that is the price of the
single-digit-nanomolar Ki.
The human SERT S1 pocket (visualized here in PDB 5I73) is conformationally flexible,
cycling through outward-open, occluded and inward-open states of the alternating-access transport cycle.
Shannon entropy analysis of the pocket shows high H_pocket in the apo transporter (many
accessible conformers) that collapses sharply when escitalopram traps the outward-open state —
the thermodynamic fingerprint of a high-affinity competitive inhibitor. Crucially, the second escitalopram
at the allosteric S2 vestibule caps the extracellular release pathway, further reducing
the conformational phase space available to the scaffold domain and lowering koff
from S1. Allosteric occupancy is, in entropic terms, a second collapse layered on the first.
Theoretical binding free energy from the observed S1 affinity:
ΔG = −RT·ln(1/Kd) with Kd ≈ 1.0 nM gives
ΔG ≈ −12.3 kcal/mol at 298 K — a high-affinity, enthalpy-anchored (salt bridge +
aromatic stacking) complex with a favorable rigid-core entropy profile. The (R)-enantiomer, by contrast,
docks the same S1 pocket ~36-fold weaker and preferentially occupies S2, where its role is
negative allosteric modulation rather than transport blockade — the structural reason a racemic
mixture is thermodynamically inferior to pure escitalopram.
Evidence-based, non-moralistic. Escitalopram is one of the safest antidepressants in overdose, but three risks are non-negotiable: serotonin syndrome from combinations, dose-dependent QT prolongation, and discontinuation on abrupt stop.
68P) at
both the central (S1) and allosteric (S2) sites, 3.24 Å (Coleman, Green & Gouaux, 2016,
Nature 532:334). The central-site-only complex is PDB 5I71. Rotate · scroll to zoom · right-drag to translate.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
SERT · S1
Serotonin transporter (central site)
|
Ki = 1.0 nM
pChEMBL 9.0
|
Reuptake inhibitor | |
|
SERT · S2
Serotonin transporter (allosteric)
|
low-µM
↓ koff from S1
|
Allosteric (self) | |
|
(R)-citalopram
SERT — enantiomer, for contrast
|
Ki = 36 nM
|
NAM of (S) | |
|
NET
Norepinephrine transporter
|
Ki ≈ 6,500 nM
|
Negligible | |
|
DAT
Dopamine transporter
|
Ki > 10,000 nM
|
Negligible | |
|
hERG
Kv11.1 cardiac channel
|
IC50 ~ low-µM
|
Blocker (QT) | |
|
H₁ / M / α₁ / 5-HT
Off-target receptor panel
|
Ki ≫ 1,000 nM
|
Silent |